logo
Why Kratos Defense Stock Topped the Market on Monday

Why Kratos Defense Stock Topped the Market on Monday

Yahoo21 hours ago
Key Points
This company sure didn't have a case of the Mondays, as several analysts made bullish adjustments to their existing takes.
Meanwhile, another pundit launched coverage of the stock with a buy rating.
10 stocks we like better than Kratos Defense & Security Solutions ›
There's nothing like an estimates-beating quarter to bring a lingering bull stampede into a stock.
Buoyed by good quarterly results it delivered last week and several analyst price-target boosts on Monday, Kratos Defense & Security Solutions (NASDAQ: KTOS) shares bumped higher again that session. They closed the day more than 2% higher in price, contrasting favorably with the 0.3% dip of the S&P 500 index.
Time to go on offense with this defense stock
Those bullish adjustments from pundits started flowing in on Friday, following Kratos' earnings release, and continued into the new week.
Monday morning, both B. Riley and Noble Capital lifted their price targets on the defense stock and steadfastly maintained their equivalent of buy recommendations. The former's Mike Crawford now feels the stock is worth $72 per share, well up from his previous fair value assessment of $55. Joe Gomes from the latter company hiked his price target by 25% to $75 per share from $60.
As if to put an exclamation point on Kratos' solid second-quarter performance, one researcher even initiated coverage with its own buy rating. This was Cannacord Genuity's Austin Moeller. Essentially in line with his two peers, he believes the company's shares could reach a price of $74 apiece.
Lingering bullishness
We can't really blame any investor or analyst for being optimistic about Kratos' future, given how satisfying some of those quarterly figures were. One that particularly stood out was the company's 17% year-over-year rise in sales, which is considerable for a company that's large and well established in its market.
Do the experts think Kratos Defense & Security Solutions is a buy right now?
The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Kratos Defense & Security Solutions make the list?
When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,060% vs. just 182% for the S&P — that is beating the market by 877.59%!*
Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!*
The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of August 11, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Why Kratos Defense Stock Topped the Market on Monday was originally published by The Motley Fool
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Antofagasta posts 60% increase in core earnings in first half
Antofagasta posts 60% increase in core earnings in first half

Yahoo

time9 minutes ago

  • Yahoo

Antofagasta posts 60% increase in core earnings in first half

LONDON (Reuters) -Chilean miner Antofagasta posted a 60% increase in half-year core earnings on Thursday, on higher production and sales of its copper. Earnings before interest, tax, depreciation and amortisation (EBITDA) for the first six months of the year rose to $2.2 billion from $1.39 billion last year, in line with analysts' consensus expectations. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Jefferies Group's Strategic Moves: SPDR S&P 500 ETF Trust Takes Center Stage with 2. ...
Jefferies Group's Strategic Moves: SPDR S&P 500 ETF Trust Takes Center Stage with 2. ...

Yahoo

time9 minutes ago

  • Yahoo

Jefferies Group's Strategic Moves: SPDR S&P 500 ETF Trust Takes Center Stage with 2. ...

Analyzing Jefferies Group (Trades, Portfolio)'s Latest 13F Filing for Q2 2025 Introduction to Jefferies Group (Trades, Portfolio) Jefferies Group (Trades, Portfolio) recently submitted its 13F filing for the second quarter of 2025, offering a glimpse into its strategic investment decisions. Founded by Harvard graduates Ian Cummings and Joseph S. Steinberg, the company initially took control of Talcott National Corporation in 1980, renaming it Leucadia National. In 2013, Jefferies Group (Trades, Portfolio) acquired the company, with Richard Handler stepping in as CEO. By 2018, it was rebranded as Jefferies Financial Group (JEF). Jefferies Group (Trades, Portfolio) operates through various subsidiaries, engaging in investment banking, telecommunications, healthcare services, and more. The firm follows a value investing approach, focusing on acquiring distressed companies at discounted prices, revitalizing them, and selling for profit. Their strategy emphasizes not overpaying, investing in essential products or services, and valuing sheltered earnings over taxed ones. Summary of New Buy Jefferies Group (Trades, Portfolio) added a total of 210 stocks, among them: The most significant addition was Marex Group PLC (NASDAQ:MRX), with 1,038,967 shares, accounting for 0.35% of the portfolio and a total value of $41.01 million. The second largest addition to the portfolio was Couchbase Inc (NASDAQ:BASE), consisting of 1,524,681 shares, representing approximately 0.32% of the portfolio, with a total value of $37.17 million. The third largest addition was uniQure NV (NASDAQ:QURE), with 2,095,931 shares, accounting for 0.25% of the portfolio and a total value of $29.22 million. Key Position Increases Jefferies Group (Trades, Portfolio) also increased stakes in a total of 274 stocks, among them: The most notable increase was SPDR S&P 500 ETF Trust (SPY), with an additional 498,285 shares, bringing the total to 1,318,891 shares. This adjustment represents a significant 60.72% increase in share count, a 2.65% impact on the current portfolio, with a total value of $814,876,590. The second largest increase was iShares Russell 2000 ETF (IWM), with an additional 283,563 shares, bringing the total to 849,018. This adjustment represents a significant 50.15% increase in share count, with a total value of $183,209,620. Summary of Sold Out Jefferies Group (Trades, Portfolio) completely exited 556 holdings in the second quarter of 2025, as detailed below: Lions Gate Entertainment Corp (NYSE:LGF.A): Jefferies Group (Trades, Portfolio) sold all 3,725,000 shares, resulting in a -0.3% impact on the portfolio. Sabra Health Care REIT Inc (NASDAQ:SBRA): Jefferies Group (Trades, Portfolio) liquidated all 1,466,000 shares, causing a -0.23% impact on the portfolio. Key Position Reduces Jefferies Group (Trades, Portfolio) also reduced positions in 318 stocks. The most significant changes include: Reduced Apple Inc (NASDAQ:AAPL) by 532,930 shares, resulting in a -80.04% decrease in shares and a -1.06% impact on the portfolio. The stock traded at an average price of $202.27 during the quarter and has returned 9.70% over the past 3 months and -6.49% year-to-date. Reduced Alphabet Inc (NASDAQ:GOOGL) by 384,391 shares, resulting in a -96.97% reduction in shares and a -0.53% impact on the portfolio. The stock traded at an average price of $163.55 during the quarter and has returned 26.75% over the past 3 months and 6.94% year-to-date. Portfolio Overview At the second quarter of 2025, Jefferies Group (Trades, Portfolio)'s portfolio included 1,118 stocks. The top holdings included 7.01% in SPDR S&P 500 ETF Trust (SPY), 1.58% in iShares Russell 2000 ETF (IWM), 1.25% in INVESCO QQQ Trust (NASDAQ:QQQ), 1.02% in SPDR Biotech ETF (XBI), and 1.01% in Mastercard Inc (NYSE:MA). The holdings are mainly concentrated in all 11 industries: Healthcare, Financial Services, Technology, Industrials, Energy, Consumer Cyclical, Communication Services, Consumer Defensive, Real Estate, Utilities, and Basic Materials. This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Vanguard Health Care Fund's Strategic Moves: Johnson & Johnson Takes Center Stage with 2. ...
Vanguard Health Care Fund's Strategic Moves: Johnson & Johnson Takes Center Stage with 2. ...

Yahoo

time9 minutes ago

  • Yahoo

Vanguard Health Care Fund's Strategic Moves: Johnson & Johnson Takes Center Stage with 2. ...

Exploring the Latest Investment Strategies of Vanguard Health Care Fund (Trades, Portfolio) Vanguard Health Care Fund (Trades, Portfolio) recently submitted its N-PORT filing for the second quarter of 2025, shedding light on its strategic investment decisions during this period. Managed by Jean M. Hynes, CFA, CEO of Wellington Management Company, the fund is renowned for its focus on long-term capital appreciation within the health care sector. Wellington Management Company, established in 1928, is one of the oldest and most respected institutional investment managers in the United States, advising the Vanguard Health Care Fund (Trades, Portfolio) since 1984. The fund aims to maintain a diversified exposure across five primary subsectors: health services, medical products, specialty pharmaceuticals, major pharmaceuticals, and international markets. Its investment philosophy emphasizes companies with robust balance sheets, strong management, and potential for innovative products that could drive above-average growth in revenue and earnings. The fund's contrarian style often leads to purchasing stocks after negative events have caused a decline in share price. Summary of New Buy Vanguard Health Care Fund (Trades, Portfolio) added a total of eight stocks, with the most significant addition being Johnson & Johnson (NYSE:JNJ). The fund acquired 4,660,244 shares, which now account for 2.05% of the portfolio, with a total value of $711.85 million. The second largest addition was Roche Holding AG (XSWX:ROG), consisting of 1,677,044 shares, representing approximately 1.58% of the portfolio, with a total value of CHF 547,420,130. The third largest addition was Gilead Sciences Inc (NASDAQ:GILD), with 4,823,087 shares, accounting for 1.54% of the portfolio and a total value of $534.74 million. Key Position Increases Vanguard Health Care Fund (Trades, Portfolio) also increased stakes in a total of 16 stocks. The most notable increase was in Elevance Health Inc (NYSE:ELV), with an additional 507,005 shares, bringing the total to 1,700,286 shares. This adjustment represents a significant 42.49% increase in share count, a 0.57% impact on the current portfolio, with a total value of $661.34 million. The second largest increase was in Cencora Inc (NYSE:COR), with an additional 501,886 shares, bringing the total to 2,279,215. This adjustment represents a significant 28.24% increase in share count, with a total value of $683.42 million. Summary of Sold Out Vanguard Health Care Fund (Trades, Portfolio) completely exited 12 holdings in the second quarter of 2025. Notable exits include Blueprint Medicines Corp (BPMC), where the fund sold all 1,362,970 shares, resulting in a -0.32% impact on the portfolio. Another significant exit was Surgery Partners Inc (NASDAQ:SGRY), with the liquidation of all 4,602,252 shares, causing a -0.29% impact on the portfolio. Key Position Reduces Vanguard Health Care Fund (Trades, Portfolio) also reduced its position in 45 stocks. The most significant changes include a reduction in Novartis AG (XSWX:NOVN) by 5,691,220 shares, resulting in a -49.44% decrease in shares and a -1.66% impact on the portfolio. The stock traded at an average price of CHF 93.19 during the quarter and has returned 8.24% over the past three months and 13.88% year-to-date. Another notable reduction was in Edwards Lifesciences Corp (NYSE:EW) by 6,663,224 shares, resulting in a -37.32% reduction in shares and a -1.27% impact on the portfolio. The stock traded at an average price of $74.55 during the quarter and has returned 2.89% over the past three months and 4.93% year-to-date. Portfolio Overview As of the second quarter of 2025, Vanguard Health Care Fund (Trades, Portfolio)'s portfolio included 81 stocks. The top holdings included 10.78% in Eli Lilly and Co (NYSE:LLY), 6.49% in AstraZeneca PLC (LSE:AZN), 5.56% in UnitedHealth Group Inc (NYSE:UNH), 4.52% in Merck & Co Inc (NYSE:MRK), and 4.35% in Boston Scientific Corp (NYSE:BSX). The holdings are mainly concentrated in one of the 11 industries: Healthcare. This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein. This article first appeared on GuruFocus.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store